Amedisys Inc (NASDAQ:AMED) Stock Rating Upgraded by Benchmark Co.

Amedisys Inc (NASDAQ:AMED) was upgraded by Benchmark Co. from a “hold” rating to a “buy” rating in a report released on Thursday, November 2nd, Marketbeat Ratings reports. The brokerage presently has a $56.00 price target on the health services provider’s stock. Benchmark Co.’s price target would suggest a potential upside of 1.87% from the company’s current price.

AMED has been the subject of several other reports. Mizuho upgraded shares of Amedisys from a “neutral” rating to a “buy” rating and increased their price objective for the company from $55.00 to $65.00 in a report on Thursday, November 2nd. BidaskClub upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Thursday, October 12th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Monday, October 9th. Finally, Robert W. Baird reiterated a “hold” rating and issued a $50.00 price objective on shares of Amedisys in a report on Wednesday, October 4th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Amedisys currently has an average rating of “Buy” and an average price target of $61.00.

Amedisys (AMED) opened at $54.97 on Thursday. Amedisys has a 1 year low of $38.00 and a 1 year high of $65.91. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. The company has a market cap of $1,866.86, a PE ratio of 26.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.68.

Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, topping the consensus estimate of $0.54 by $0.02. The firm had revenue of $380.20 million during the quarter, compared to analysts’ expectations of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. Amedisys’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.36 EPS. sell-side analysts forecast that Amedisys will post 2.23 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/amedisys-inc-amed-upgraded-to-buy-at-benchmark-co/1752021.html.

Large investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. boosted its holdings in Amedisys by 23.9% during the second quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock worth $915,000 after buying an additional 2,812 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Amedisys by 1.5% in the 2nd quarter. Victory Capital Management Inc. now owns 702,239 shares of the health services provider’s stock valued at $44,108,000 after acquiring an additional 10,080 shares in the last quarter. Thrivent Financial For Lutherans lifted its position in shares of Amedisys by 3.8% in the 1st quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock valued at $802,000 after acquiring an additional 570 shares in the last quarter. Castleark Management LLC purchased a new stake in shares of Amedisys in the 2nd quarter valued at approximately $3,674,000. Finally, Vanguard Group Inc. lifted its position in shares of Amedisys by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock valued at $121,067,000 after acquiring an additional 63,238 shares in the last quarter. Hedge funds and other institutional investors own 93.94% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.